AUTHOR=Blass Benjamin E. , Puri Sumant , Sharma Rishabh , Day Brian M. 

TITLE=Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs

JOURNAL=Frontiers in Drug Discovery

VOLUME=2

YEAR=2022

URL=https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2022.1000827

DOI=10.3389/fddsv.2022.1000827

ISSN=2674-0338

ABSTRACT=<p>Invasive candidiasis remains a significant health concern, as it is associated with a high mortality risk. In addition, the risk of infection is significantly elevated in immunocompromised patients such as those with HIV, cancer, or those taking imcmunosuppressive drugs as a result of organ transplantation. The majority of these cases are caused by <italic>C. albicans</italic>, and <italic>C. glabrata</italic> is the second most common cause. These infections are typically treated using approved antifungal agents, but the rise of drug-resistant fungi is a serious concern. As part of our on-going effort to identify novel antifungal agents, we have studied the <italic>in vitro</italic> antifungal properties of a series of sulfonamide analogs of (2S, 4R)-Ketoconazole. Herein we report on the <italic>in vitro</italic> activity against the key fungal pathogens <italic>C. albicans</italic>, and <italic>C. glabrata</italic>.</p>